{"entity":{"id":"ariceum-therapeutics","kind":"company","name":"Ariceum Therapeutics","aka":[],"tldr":"Ariceum Therapeutics is a Berlin company that was developing a treatment carrying the alpha-emitting isotope actinium-225 to small cell lung cancer and Merkel cell skin cancer. Its first human trial was stopped after two patients, which the trial record puts down to business decisions.","summary":"Ariceum Therapeutics is a Berlin-based targeted radiotherapeutics company. Its lead candidate 225Ac-SSO110 is an actinium-225 labelled radioligand for extensive-stage small cell lung cancer (ES-SCLC) and Merkel cell carcinoma (MCC). The phase 1/2 SANTANA-225 study (NCT06939036) was planned to start in the second half of 2025, with initial safety data expected in early 2026 and preliminary efficacy findings in 2027. Its ClinicalTrials.gov record, last updated in February 2026, lists the study as terminated after enrolling 2 patients, with the reason given as strategic business decisions. In August 2025 David Schilansky, previously CFO, succeeded co-founder Manfred Rüdiger as CEO alongside a new executive team.","asOf":"2026-10-29","links":[{"label":"CEO appointment release, August 2025 (BioSpace copy)","url":"https://www.biospace.com/press-releases/ariceum-therapeutics-appoints-david-schilansky-as-chief-executive-officer-and-announces-new-leadership-to-advance-next-phase-of-development"},{"label":"ClinicalTrials.gov: SANTANA-225, terminated (NCT06939036)","url":"https://clinicaltrials.gov/study/NCT06939036"}],"tags":[],"related":[],"cancers":["sclc"],"sections":["radiopharma"],"technologies":["targeted-alpha-therapy","radioligand-therapy"],"targets":[],"drugs":[],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":["No website is recorded. The company domain ariceum-therapeutics.com returned a certificate error and then an HTTP 500 'Database Error' in September 2026, and still returned the same database error on 29 October 2026, so there is no working company site to link to. Whether the company is still operating could not be confirmed: the terminated trial is the latest primary record found, and no company statement about it was reached. Series A (reported elsewhere as EUR 25 million in 2022) and the Theragnostics acquisition are unsourced and omitted. SSO110 target (SSTR2 antagonist per other reports) not stated in the fetched text."],"hq":"Berlin","country":"DE","companyType":"radiopharma","stage":"startup","investors":[],"funding":[]},"route":"/companies/ariceum-therapeutics/","neighbours":{"cancer":[{"id":"sclc","kind":"cancer","name":"Small-cell lung cancer","route":"/cancers/sclc/"}],"section":[{"id":"radiopharma","kind":"section","name":"Radiopharmaceuticals & Theranostics","route":"/fronts/radiopharma/"}],"technology":[{"id":"radioligand-therapy","kind":"technology","name":"Radioligand therapy (beta emitters)","route":"/technologies/radioligand-therapy/"},{"id":"targeted-alpha-therapy","kind":"technology","name":"Targeted alpha therapy","route":"/technologies/targeted-alpha-therapy/"}]}}